Feeding silk protein hydrolysates to C57BL/KsJ-db/db mice improves blood glucose and lipid profiles

Nutrition Research

Volumn 30, Issue 11, 2010, Pages 783-790

  Jung, Eun Young ^a   Lee, Hyun Sun ^a   Lee, Hyun Jung ^a   Kim, Jin Man ^b   Lee, Kwang Won ^a   Suh, Hyung Joo ^a  

^a Korea University   (South Korea)

^b Konkuk University   (South Korea)

Author keywords

C57BL KsJ db db mice; Diabetes; Insulin stimulating activity; Pancreatic beta cells; Silk protein hydrolysate

Indexed keywords

ADIPONECTIN; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN HYDROLYSATE; SILK PROTEIN HYDROLYSATE E5K6; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; BLOOD GLUCOSE MONITORING; C57BL MOUSE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; DYSLIPIDEMIA; FOOD INTAKE; FUNCTIONAL MORPHOLOGY; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; WEIGHT GAIN;

ADIPONECTIN; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; BOMBYX; CHOLESTEROL, LDL; DIET, ATHEROGENIC; GLUCAGON; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; MALE; MICE; MICE, INBRED C57BL; PROTEIN HYDROLYSATES; SILK;

MUS;

EID: 78649816911     PISSN: 02715317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nutres.2010.10.006     Document Type: Article

References (27)

1. Salvatore T., Carbonara O., Cozzolino D., Torella R., Sasso F.C. Progress in the oral treatment of type 2 diabetes: update on DPP-IV inhibitors. Curr Diabetes Rev 2009, 5:92-101.
2. Zhang B.B., Moller D.E. New approaches in the treatment of type 2 diabetes. Curr Opin Chem Biol 2000, 4:461-467.
3. Yeh G.Y., Eisenberg D.M., Kaptchuk T.J., Phillips R.S. Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 2003, 26:1277-1294.
4. Ahmad R., Kamra A., Hasnain S.E. Fibroin silk proteins from the nonmulberry silkworm Philosamia ricini are biochemically and immunochemically distinct from those of the mulberry silkworm Bombyx mori. DNA Cell Biol 2004, 23:149-154.
5. Altman G.H., Diaz F., Jakuba C., Calabro T., Horan R.L., Chen J., et al. Silk-based biomaterials. Biomaterials 2003, 24:401-416.
6. Sprague K.U. The Bombyx mori silk proteins: characterization of large polypeptides. Biochemistry 1975, 14:925-931.
7. Min B.M., Jeong L., Nam Y.S., Kim J.M., Kim J.Y., Park W.H. Formation of silk fibroin matrices with different texture and its cellular response to normal human keratinocytes. Int J Biol Macromol 2004, 34:281-288.
8. Liu Y., Chen X., Qian J., Liu H., Shao Z., Deng J., et al. Immobilization of glucose oxidase with the blend of regenerated silk fibroin and poly (vinyl alcohol) and its application to a 1,1'-dimethylferrocene-mediating glucose sensor. Appl Biochem Biotechnol 1997, 62:105-117.
9. Hanawa T., Watanabe A., Tsuchiya T., Ikoma R., Hidaka M., Sugihara M. New oral dosage form for elderly patients. II. Release behavior of benfotiamine from silk fibroin gel. Chem Pharm Bull (Tokyo) 1995, 43:872-876.
10. Singh T.M., Kadowaki M.H., Glagov S., Zarins C.K. Role of fibrinopeptide B in early atherosclerotic lesion formation. Am J Surg 1990, 160:156-159.
11. Gotoh K., Izumi H., Kanamoto T., Tamada Y., Nakashima H. Sulfated fibroin, a novel sulfated peptide derived from silk, inhibits human immunodeficiency virus replication in vitro. Biosci Biotechnol Biochem 2000, 64:1664-1670.
12. Lim W.T., Lee J.Y., Yeon S.H., Lee J.C. Processing method of silk peptide (Patent No. 0881210) KFDA 2009, Republic of Korea.
13. Reeves P.G., Nielsen F.H., Fahey G.C. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993, 123:1939-1951.
14. Han G.C., Ko S.K., Sung J.H., Chung S.H. Compound K enhances insulin secretion with beneficial metabolic effects in db/db mice. J Agric Food Chem 2007, 55:10641-10648.
15. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low density lipoprotein cholesterol without use of preperative ultra centrifuge. Clin Chem 1972, 18:499-502.
16. Kim M.J., Chang U.J., Chung J.H., Kim H.K., Lim B.O., Yamada K., et al. Dissimilarity in Fos and Jun immunoreactivity in hypothalamic regions between obese and lean Zucker rats. Biosci Biotechnol Biochem 2005, 69:1982-1984.
17. Basciano H., Federico L., Adeli K. Fructose, insulin resistance, and metabolic dyslipidemia. Nutr Metab (Lond) 2005, 2:5.
18. Kasai S., Inoue T., Yoshitomi H., Hihara T., Matsuura F., Harada H., et al. Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs. J Pharmacol Sci 2008, 108:40-48.
19. Bell D.S. Diabetes: a cardiac condition manifesting as hyperglycemia. Endocr Pract 2008, 14:924-932.
20. Chait A., Bornfeldt K.E. Diabetes and atherosclerosis: is there a role for hyperglycemia?. J Lipid Res 2009, 50(Suppl):S335-S339.
21. Chen H., Charlat O., Tartaglia L.A., Woolf E.A., Weng X., Ellis S.J., et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996, 84:491-495.
22. Kaku K., Province M., Permutt M.A. Genetic analysis of obesity-induced diabetes associated with a limited capacity to synthesize insulin in C57BL/KS mice: evidence for polygenic control. Diabetologia 1989, 32:636-643.
23. Orland M.J., Permutt M.A. Quantitative analysis of pancreatic proinsulin mRNA in genetically diabetic (db/db) mice. Diabetes 1987, 36:341-347.
24. Kodama H., Fujita M., Yamaguchi I. Development of hyperglycaemia and insulin resistance in conscious genetically diabetic (C57BL/KsJ-db/db) mice. Diabetologia 1994, 37:739-744.
25. Nahm J., Oh Y. A study of pharmacological effect of silk fibroin. RDA J Agric Sci 1995, 37:145-157.
26. Cho M.R., Choue R., Chung S.H., Ryu J.W. Effects of silkworm powder on blood glucose and lipid levels in NIDDM (type 2) patients. Korean J Nutr 1998, 31:1139-1150.
27. Hui H., Tang G., Go V.L. Hypoglycemic herbs and their action mechanisms. Chin Med 2009, 4:11.